What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

The study aims to explore the role of Eubacterium rectale and its metabolite butyrate in gastric cancer treatment and immunotherapy efficacy.

March 14, 2026Journal of Translational MedicineOpen Access

Butyrate-producing Eubacterium rectale inhibits gastric carcinogenesis and augments the efficacy of immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

WGWei Gao JXJiani Xiong GWGuangfeng Wu

Discussion

Member takes

Overview

Prospective cohort reveals immunotherapy improves progression-free survival in gastric cancer, highlighting gut microbiota's role in overcoming therapeutic resistance.

Key Points

The study aims to explore the role of Eubacterium rectale and its metabolite butyrate in gastric cancer treatment and immunotherapy efficacy.
Analyzed a prospective gastric cancer cohort for Eubacterium rectale association with immunotherapy outcomes.
Conducted in vitro and in vivo experiments to assess tumor growth, apoptosis, and immune cell infiltration.
Performed targeted metabolomics on gut, serum, and tumor samples to measure short-chain fatty acid distribution.
Eubacterium rectale and butyrate significantly inhibited tumor growth and promoted apoptosis.
Treatment led to reduced PD-L1 expression and increased CD8+ T-cell infiltration in mouse models.
Observations suggest that gut microbiota enhances progression-free survival and overcomes immunotherapy resistance.

Cite This Study

Gao et al. (2026) studied this question.

synapsesocial.com/papers/69b4adb518185d8a398016ef https://doi.org/10.1186/s12967-026-07986-6

View Full Paper

Ask AI

Bookmark

March 14, 2026Journal of Translational MedicineOpen Access

Butyrate-producing Eubacterium rectale inhibits gastric carcinogenesis and augments the efficacy of immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

WGWei Gao JXJiani Xiong GWGuangfeng Wu

Discussion

Member takes

Overview

Prospective cohort reveals immunotherapy improves progression-free survival in gastric cancer, highlighting gut microbiota's role in overcoming therapeutic resistance.

Key Points

The study aims to explore the role of Eubacterium rectale and its metabolite butyrate in gastric cancer treatment and immunotherapy efficacy.
Analyzed a prospective gastric cancer cohort for Eubacterium rectale association with immunotherapy outcomes.
Conducted in vitro and in vivo experiments to assess tumor growth, apoptosis, and immune cell infiltration.
Performed targeted metabolomics on gut, serum, and tumor samples to measure short-chain fatty acid distribution.
Eubacterium rectale and butyrate significantly inhibited tumor growth and promoted apoptosis.
Treatment led to reduced PD-L1 expression and increased CD8+ T-cell infiltration in mouse models.
Observations suggest that gut microbiota enhances progression-free survival and overcomes immunotherapy resistance.

Cite This Study

Gao et al. (2026) studied this question.

synapsesocial.com/papers/69b4adb518185d8a398016ef https://doi.org/10.1186/s12967-026-07986-6

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark